Damian Garde

Biography for Damian Garde

Damian Garde, Editor

Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at dgarde@fiercemarkets.com and follow @DamianFierce on Twitter.

Articles by Damian Garde

Actelion taps DKSH to break into Asia

Market-access contractor DKSH has signed a deal with Actelion Pharmaceuticals to help the company bolster its position in Asia.

U.K. CRO conglomerate bags another testing outfit with eyes on toxicology

Concept Life Sciences, a CRO pieced together through a string of acquisitions, has inked a deal to acquire a toxicology-focused contractor, looking to expand its palate of drug development services.

Evotec's hybrid R&D model keeps revenue rolling

Germany's Evotec grew its revenue 37% in the first half of 2015, as its CRO-like business brought in cash to support the company's in-house R&D.

WuXi watches profits slip on its way to going private

Chinese CRO WuXi Pharma posted more soaring revenue in the second quarter, but some costly investments and currency issues drove down the company's profits as it prepares to go private.

INC's backers line up for a big Wall Street payday

The deep-pocketed outfits that helped take INC Research public last year are angling to cash in on the CRO's resulting success on the market, flipping shares in a secondary offering.

Accelovance adding 70 jobs in Wales after a big EU buy

U.S. CRO Accelovance is blueprinting a new site in Wales, planning to add 70 positions as it builds out its European ranks.

WuXi advances edible bar codes, a novel approach to counter-counterfeiting

Chinese CRO WuXi PharmaTech, alongside partner TruTag Technologies, is developing tiny, edible bar codes designed to prevent drug counterfeiting, and the technology cleared its first hurdle.

Another Indian CRO draws the ire of Western regulators

An Indian CRO that counts Johnson & Johnson, Novartis and Sanofi among its clients is under fire from the FDA for repeated quality control issues, the latest ding to the country's reputation as a go-to destination for outsourced drug development.

Chiltern buys Theorem to compete with CRO heavyweights

Two mid-size CROs are slated to merge and contend with the industry's titans, as Chiltern is buying Theorem Clinical Research in a move to strengthen its global presence.

Patheon signs up to manufacture Flexion's lead drug

Contract drugmaker Patheon inked a deal to manufacture Flexion Therapeutics' top prospect as it moves through clinical development.